Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

80 HIV-1 * HIV-1
n/7-year trends in adult
of SIV and the origin of
Tanzania/Incidence of
lecular epidemiology of
ng/Genetic diversity of
A)/Characterization of
alence and incidence of
ants in Tanzania/V3 of
DNA during pregnancy/
I/Seroepidemiology of
pecificity for serotyping
ypic characterization of
ecular epidemiology of
n Bangkok, Thailand/
ogic characterization of
wo distinct subtypes of
acterization of incident
/Surveillance trends of
ecular epidemiology of
mple method for typing
pines/V3 serotyping of
ning seroprevalence of
s for new infection with
wan/Rapid detection of
pes in young Thai men/
ecular epidemiology of
y analysis of subtype E
nd/Genetic diversity of
HIV epidemic in Brazil/
from Sao Paulo, Brazil/
ng in Sao Paulo, Brazil/
graphic characteristics/
Argentina/At least four
pidemic in Kaliningrad/
ion in southern France/
etic characterization of
als in The Netherlands/
tzerland/Distribution of
96-1997/Prevalence of
/Increasing diversity of
ero- and genotyping of
infection in Russia and
lecular epidemiology of
types in different cities/
demic/Epidemiology of
nvertors/Prevalence of
vidence for evolution of
tates/Prevalence of
Abidjan, C6te d'lvoire/
ala, Uganda/Trends of
echanism for enhanced
son of survival between
rum malaria illness and
Us) newly infected with
I-associated infectious
en cohorts infected with
nfection as compared to
ectin variant alleles on
Patterns of longitudinal
bidjan, C6te d'lvoire/
bidjan, C6te d'lvoire/
DS up to 1996 in 13,000
ase progression in 664
disease progression in
s genetic background of
nuated quasi species of
r verically infected with
ted children/Pattern of
en with recent perinatal
ts/CCR5 genotype and

ssociated with perinatal
progression in perinatal
r-specific differences in
infected recipients of a
e relationship between
ulo, Brazil/Detection of
es differ in time to AIDS/
ouse system/Control of
ymphocyte depletion in
/Infection with different

12th World AIDS Conference

-Keyword

Abstract

-Keyword

Abstract
prevalence, incidence and mortality i 13106 ance to mother-to-child
and HIV-2 in Africa: The role of unste 13107 CD4 and CD8 T-cells in
infection and associated risk factors i 13108 ogical characteristics of
in Uganda/The molecular epidemiol 431*/13109 al therapy/Induction of
in Tanzania: Use of heteroduplex mo 13110 markers/Symptomatic
subtypes in Senegal by heteroduple 13112 genitor cells (CD34+) of
infection in population-based studies 13114 mino acid signatures of
subtype C is over-represented in inte 13115 D4 Thl cells specific for
subtype and shedding of cervicovagi 13117 ransition to progressive
/2 infections among patients attendin 13120 s in vivo correlates with
in Uganda by use of V3 and gp41 env 13121 ection from subsequent
from migrant workers on three South 13122 ood-brain barrier during
in KwaZulu-Natal, Gauteng and the 13125 okines/Upregulation of
incidence, subtypes, and follow-up in 13127 nal transduction due to
in Myanmar (Burma)/Genetic and se 13130 r by human monocytes/
among injecting drug users in southe 13131 rion/Saliva neutralizes
subtype B and E strains from injectin 13133 diate significantly less
subtypes B' and E throughout Thaila 13134 nd Th2-type conditions/
infection in the Philippines, 1985-19 13137 nd inhibits apoptosis/
(B, E) by PCR: Chronological shift of 13138 tus (NuMA) protein by
infection in the Philippines/V3 seroty 13140 se activity/The effect of
among child-bearing women in uppe 13143 of HIV-1 infected cells/
subtypes B' and E among injecting dr 13144 ring of CD30 enhances
subtype E infection by polymerase c 13146 ix with a primary isolate
seroprevalence and distribution of se 13147 reased susceptibility to
in Taiwan: Heterosexual males with 13148 ypic characterization of
strains epidemic in Shenzhen/Molec 13149 al features for Russian
subtype E from recent seroconverter 13155 duction of interferon by
dual infections and recombinants are 13156 lecules during primary
subtypes B and F circulating in childr 13157 ential effects of IL-4 on
subtypes circulating in Sao Paulo, Br 434*/13162 els during the course of
subtyping in Bahia, Brazil: A state wit 13169 eutralization of primary
genotypes circulate in Rosario, Arge 13175 g immune responses to
genetic subtype A/B recombinant str 13190 ects with other subtype
clade distribution in southern France 13193 duced by a consecutive
in Russia: Evidence of increasing inf 13194 combinant gp120 SF2/
subtypes and viruses specific for Dut 13195 e distribution and fate of
env subtypes in patients in Switzerla 13198 cid vaccination against
subtypes in France, 1996-1997/Pre 13199 ctored vaccine against
serotypes in French blood donors (1 13204 s vector/Antigenicity of
variants circulating on the territory of 13205 y designed vaccines for
subtypes isolated in Russia in 1994- 436*/13206 negative infants born to
in Switzerland/Molecular epidemiolo 13207 A immunization against
sero- and genotyping of HIV/AIDS o 13209 0-depleted inactivated
seroconversion among young adults 518*/13212 al immunizing route for
resistance mutations in a US military 13215 munization with a novel
within behavioral risk groups in San 13217 uberculosis infection in
group M, non-B subtypes in a Bronx, 13225 ulosis (TB) treatment in
RNA plasma viral load and CD4 cou 13271 nii and T. gondii in adult
infection among pulmonary tubercul 610*/13273 lence of co-infection by
transmission?/lncreased IL-10 in th 13280 une status in a cohort of
and HIV-2 in the Gambia, West Afric 13294 thelial neoplasia/Local
RNA viral burden/The association b 13297 plasia/Relationship of
subtypes B' and E, Bangkok/Viral lo 191*/13302 undetermined origin in
viral load beneficial in predicting HIV 13308 nd lamivudine (3TC) in
subtypes B and C/Comparison of vir 13314 DV) versus indinavir in
infection/Incidence of disease after 13319 saquinavir) therapy in
disease progression in 426 patients 13320 ollowing treatment with
viral load after seroconversion assoc 13322 tification of reservoir of
plasma viral load in tuberculosis pati 13328 amivudine (HAART) in
plasma viral load and CD4 counts in 13329 vs. 3TC + d4T + SQV in
seroconverters/Survival and progre 13337 e or AZT - Experienced
seroconverted injecting drug users in 192*/13338 apy initiated at primary
infection/Psychological and neurops 595*/13345 nalogue experienced
infected long-term non-progressors i 12*/13346 udine, and indinavir in: Long-term non-progression/The Sy 13350 P/ddl/3TC) for the IVDU: Immunologic characterization/High 13356 ariable suppression of
RNA load from birth to school-age in 13361 n during combined anti
infection/Increase based AIDS-free 13362 nes/Immunotherapy for
infection in perinatally-exposed infan 215*"/13365 IG for the prevention of
subtype E infection, Bangkok, Thaila 13366 murabutide/Inhibition of
infection/Disease progression in per 13371 actors for acquisition of
RNA level in a longitudinal study of H 13379 ya/Serodiscordance of
contaminated clotting factor concent 13380 e Gambia: Risk factors/
load and progression to AIDS/Gend 13384 mples in Quebec City/

infection in individuals treated in an e 13394 ntravenous drug users/
subtypes differ in time to AIDS/ 277*/21101 o, Brazil/Prevalence of
proliferation and pathogenesis with h 276*/21102 d transmission (LPT) of
infection/Limited CD4+ T-cell renew 270*/21103 o-infant transmission of
subtypes (B or C) result in similar im 21105 nt/Decreased perinatal

transmission/CCR-5 genotype may 11*/21107
infection until end stage disease/Inc 268*/21108
strains from patients with AIDS dem 21110
replication by influenza vaccination (I 21113
seroconversion correlates with clinic 21116
infected patients/Telomerase activit 21118
envelope sequences in human brain 21122
antigens are associated with long-ter 21126
Infection: Attenuating sequences/Lo 21127
disease progression/Adaptation to p 8*/21134
infection/In vitro evidence of HIV-2 p 21136
encephalitis/Microglia secrete chem 21138
replication by /-chemokines/Upreg 21139
envelope interactions with the CD4/ 21140
Tat protein promotes the synthesis o 21141
infection by displacing envelope gpl 21143
upregulation/The effect of mycobact 21145
strain dependent preferences in Thl 21146
Nef associates with the tumour supp 21148
protease may play a role in cytopath 21150
infection on CD45 phosphatase activ 21151
infection induces alterations in cellul 21152
replication in acutely infected primar 21153
subtype E/lnfection of human cervix 21155
infection of peripheral blood mononu 21156
subtype E isolated from blood and ge 21157
isolates/Relationships between cell 21158
/Involvement of chemokine receptor 21172
infection. Relationship with HIV-1 R 21173
expression suggest a role in viral phe 218*/21174
infection/Changes in serum interleu 21187
isolates by antisera induced upon im 550*/21194
/Multi-subtype envelope-based DNA 551*/21196
infection in Thailand: One year interi 21197
DNA and avipox vaccine regimen/Pr 549*/21198
cross-clade lymphoproliferative resp 497*/21201
DNA vaccine in BALB/c mice/Tissue 21203
toward strong systemic and mucosal 21205
clade E strain/Construction and char 21206
envelope glycoproteins from either p 21207
through the use of molecular adjuva 21208
but not HIV-2 positive mothers fail to 21210
/Three types of env and gag-containi 21211
immunogen (RemuneT) on the contr 21212
DNA vaccine/Intranasal administrati 21213
V3 recombinant multi-epitope polype 21215
infected patients with prolonged feve 22138
infected Ugandan adults/Ethambuto 454*/22140
infected individuals with stable CD4 22179
and others sexual/parenteral transmi 22195
infected adults in Entebbe, Uganda/ 130*/22236
expression in the female genital tract 22310
RNA copies in plasma and CD4 coun 22317
infected patients/Usefulness of bon 22329
infected patients [DMP 266-004]/A d 22340
infected patients receiving nucleosid 22343
experienced patients (ZDV + ddC/dd 22344
protease inhibitors/Efficacy of the co 22357
in CD4 cells in infants and children re 22358
infected children: Kinetics of immune 22362
infected patients previously treated 22376
infected adult patients/Same antiretr 22382
infection/Full compliance sustains vi 22384
infected patients: Characterization in 22386
infected individuals/Plasma viral loa 22393
infected population of the Frankfurt 22398
replication in patients treated with ne 22400
IL-2 therapy/Chemokines and chem 22416
infection using DNA based vaccines 22418
vertical transmission in Uganda/Pha 22422
replication in reservoir cells by the sa 22424
among heterosexual men: Prospecti 23150
among pregnancy women in Nairobi, 23153
and HIV-2 infection in pregnant wom 23164
infection among drug users attendin 23182

and HTLV infection in northeast Braz 23231
subtypes and co-infection with HTLV 23248:International multicentre pooled ana 456*/23266
in western Kenya/Association betwe 461*/23268
transmission following elective cesar 23272